30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of Amgen news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+34).
📊 Amgen reported $38.9B revenue and $9.4B net income for fiscal 2026.
🏦 Company maintained 6.3x debt-to-equity ratio with $8.1B free cash flow.
Slightly Bullish +25
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
AI-generated analysis
Key insights
📊 Amgen reported revenue of approximately $38.9 billion and net income of nearly $9.4 billion for the 12 months ended Sept. 30, 2026.
🏦 The company maintained a debt-to-equity ratio of roughly 6.3x and generated free cash flow of about $8.1 billion as of Dec. 31, 2025.
📈 Amgen is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion despite being a mature business.
🤝 Amgen reached a deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for tariff exemptions for three years.
🏭 Nearly 77% of Amgen's revenues in 2025 came from sales to three large distributors: McKesson, Cencora, and Cardinal Health.
💊 The company possesses six drug franchises that generate $1 billion-plus in annual revenue, providing a stable cash flow base.
📉 Amgen is characterized as an affordable option for value-conscious investors based on its significantly lower Forward P/E and P/S ratios.
📈 Bullish signals
💊Amgen maintains a diversified portfolio across oncology and rare diseases, providing a steady business model with six drug franchises generating over $1 billion in annual revenue each.
📈The company is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion, supported by its massive scale and cash generation capabilities.
🤝Amgen secured a strategic deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
📉 Risk factors
📉The company faces substantial competition from biosimilars and generics, which can erode the market share of its older products.
📉Operational risks include a heavy reliance on specific manufacturing facilities in Puerto Rico and California.
Article
The article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), highlighting Amgen's diversified business model across oncology and rare diseases versus Vertex's high-growth specialization in genetic conditions. It notes that Amgen sells primarily through three large distributors, which accounted for nearly 77% of its revenues in 2025, adding a layer of customer concentration risk to the business.
Financial data reveals that in the 12 months ended Sept. 30, 2026, Amgen generated revenue of approximately $38.9 billion and net income of nearly $9.4 billion. The company maintains a debt-to-equity ratio of roughly 6.3x and produced free cash flow of about $8.1 billion for the fiscal year ended Dec. 31, 2025.
Amgen faces competition from biosimilars and pricing pressure but is positioned to achieve roughly 3% revenue growth in 2026, reaching around $37.8 billion. The company recently reached a deal with the U.S. government to lower prices on key drugs like Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Analysts view Amgen as an affordable option for value-conscious investors due to its lower Forward P/E and P/S ratios compared to Vertex. While not a fast-growing company by sales, its scale allows it to pursue future growth through acquisitions, supported by six drug franchises generating over $1 billion in annual revenue each.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Amgen Inc. reported a positive Phase 3 clinical trial result for its drug dazodalibep in systemic Sjogren's disease, marking a significant milestone for the biopharmaceutical company. The OASIZ 301 study met its primary endpoint at Week 48, demonstrating early improvement in disease activity measures that persisted through the end of the trial period.
Following the successful clinical data, investment bank Jefferies raised its price target for Amgen stock from USD 367.00 to USD 410.00 and increased its peak sales estimate for dazodalibep significantly to USD 4.50 billion. Despite maintaining a Hold rating, the analyst upgrade reflects strong confidence in the commercial potential of the new therapy.
Amgen also delivered solid financial performance in the second quarter of 2026, with revenue rising 9.50 percent to USD 10.05 billion and earnings per share beating consensus estimates by USD 0.67. The company provided forward guidance for 2026 EPS between USD 22.30 and USD 23.50, reinforcing its growth trajectory alongside the pipeline success.
Trading on October 2, 2026, Amgen shares were up 0.61 percent to EUR 364.45, reflecting a measured market reaction to the combined news of clinical validation and financial strength. The company remains a key component of major indices including the Dow Jones Industrial Average and Nasdaq-100.
📈 Amgen's Phase 3 OASIZ 301 trial for dazodalibep met primary endpoint in Sjogren's disease.
💰 Jefferies raised Amgen price target to USD 410 and peak sales estimates to USD 4.5B.
📊 Q2 revenue grew 9.5% YoY to USD 10.05B driven by strong core business performance.
💹 Amgen reported Q2 EPS of USD 6.29, beating consensus by USD 0.67 in 2026.
🔮 Company provided 2026 EPS guidance ranging from USD 22.30 to USD 23.50.
📈 Amgen achieved a positive primary endpoint in its Phase 3 OASIZ 301 trial for dazodalibep treating systemic Sjogren's disease.
💰 Jefferies raised the price target for Amgen stock to USD 410.00 and lifted peak sales estimates for dazodalibep to USD 4.50 billion.
📊 Second-quarter revenue grew 9.50 percent year-over-year to reach USD 10.05 billion, driven by strong core business performance.
💹 Amgen reported earnings per share of USD 6.29, exceeding analyst consensus estimates by USD 0.67 in Q2 2026.
🔮 The company provided 2026 EPS guidance ranging from USD 22.30 to USD 23.50, indicating sustained profitability expectations.
🏥 Approximately 621 patients were enrolled in the Sjogren's trial, providing a robust dataset for regulatory and commercial assessment.
📉 Amgen stock traded up 0.61 percent to EUR 364.45 on October 2, 2026, following the positive catalysts.
🔍 A second Phase 3 study (OASIZ 303) is expected to complete in the fourth quarter of 2026 for further validation.
🏛️ Amgen maintains a Hold rating from Jefferies despite the bullish analyst actions and improved price targets.
📉 The average analyst 12-month target remains at USD 381.32, slightly below Jefferies' revised higher target of USD 410.00.
Bullish Signals
OASIZ 301 trial met primary endpoint for dazodalibep in Sjogren's disease.
Risk Factors
Analysts view stock as fairly valued rather than overvalued.
Average target of USD 381.32 is below Jefferies' new target.
Phase 3 study OASIZ 303 remains pending completion in Q4 2026.
Bullish Signals
Amgen successfully met the primary endpoint in its Phase 3 OASIZ 301 trial for dazodalibep in systemic Sjogren's disease, showing sustained improvement in disease activity.
Jefferies raised its price target for Amgen stock to USD 410.00 and increased peak sales estimates for dazodalibep from USD 1.00 billion to USD 4.50 billion.
Amgen (AMGN) shares closed at $407.27, marking a 3.38% decline despite broader market gains in the S&P 500 and Nasdaq. The stock underperformed the Medical sector, which also saw losses prior to today's session. This dip occurred while analysts and investors await the company's upcoming earnings disclosure.
Analysts project Amgen's quarterly earnings per share (EPS) at $5.69, representing a 0.89% increase year-over-year, with revenue estimated at $9.91 billion, up 3.68%. Full-year consensus estimates forecast EPS of $22.94 and revenue of $38.81 billion, indicating projected growth of approximately 5% for both metrics compared to the prior year.
Valuation metrics show Amgen trading at a Forward P/E ratio of 18.38, which is below the industry average of 22.46. However, the company's PEG ratio stands at 3.04, significantly higher than the Medical - Biomedical and Genetics industry average of 1.91. The stock currently holds a Zacks Rank of #3 (Hold), with recent consensus EPS estimates moving slightly lower.
📉 Shares dipped 3.38% to close at $407.27, underperforming the broader market.
🔭 Analysts project quarterly EPS of $5.69 and revenue of $9.91 billion.
💰 Amgen trades at a Forward P/E of 18.38, below the industry average.
📊 The company's PEG ratio is 3.04, higher than the industry average.
🏆 Zacks Rank #3 (Hold) with consensus EPS estimates down 0.15%.
📉 Amgen shares dipped 3.38% to close at $407.27, underperforming the broader market and lagging the Medical sector.
🔭 Analysts project quarterly EPS of $5.69 (up 0.89%) and revenue of $9.91 billion (up 3.68%) for the upcoming earnings report.
📅 Full-year consensus estimates indicate EPS of $22.94 and revenue of $38.81 billion, reflecting roughly 5% growth from the previous year.
💰 Amgen trades at a Forward P/E ratio of 18.38, offering a discount compared to the industry average of 22.46.
📊 The company's PEG ratio is 3.04, which is notably higher than the industry average of 1.91.
🏆 Amgen currently holds a Zacks Rank of #3 (Hold), with consensus EPS estimates having moved 0.15% lower in the past month.
Bullish Signals
Trades at Forward P/E of 18.38, below industry average of 22.46.
Projected quarterly revenue growth of 3.68% to $9.91 billion.
Risk Factors
Shares fell 3.38%, underperforming S&P 500 and Medical sector.
PEG ratio of 3.04 exceeds industry average of 1.91.
Consensus EPS estimates dropped 0.15% in past month.
Bullish Signals
The company trades at a Forward P/E ratio of 18.38, which represents a discount compared to its industry average of 22.46.
Analysts project quarterly revenue growth of 3.68% to $9.91 billion and full-year earnings growth of approximately 5%.
Risk Factors
Shares fell 3.38% in the latest session, underperforming both the S&P 500 and the Medical sector.
The company's PEG ratio of 3.04 is significantly higher than the industry average of 1.91, suggesting a potentially expensive valuation relative to growth.
Consensus EPS estimates have moved 0.15% lower within the past month, reflecting slight downward pressure on near-term expectations.
Amgen Inc. reported robust financial performance for the second quarter of 2026, posting revenue of USD 10.05 billion, which represents a 9.5 percent year-over-year increase. The company also delivered earnings per share of USD 6.29, significantly beating the consensus estimate of USD 5.62 by USD 0.67. This strong operational result underscores Amgen's ability to generate growth amidst a competitive landscape.
Beyond financial metrics, Amgen achieved a significant clinical milestone with positive topline Phase 3 results for its drug candidate dazodalibep in moderate-to-severe systemic Sjogren's disease, announced on September 22, 2026. While the primary endpoint was met in the OASIZ 301 trial, further studies are required before a regulatory filing can be pursued. This progress is viewed as crucial for expanding Amgen's late-stage pipeline and offsetting potential risks from patent expirations.
Analyst sentiment regarding Amgen remains mixed following these developments. Scotiabank raised its price target to USD 500.00 while maintaining an Outperform rating, citing the company's strong position. Conversely, HSBC downgraded Amgen to Hold and cut its target to USD 425.00, reflecting ongoing concerns about valuation and future competitive pressures despite the recent clinical success.
Amgen's stock traded at EUR 372.83 on September 30, 2026, with a market capitalization of USD 228.6 billion. The company provided full-year EPS guidance between USD 22.30 and USD 23.50, which aligns closely with the current analyst consensus of USD 22.94. Investors are now weighing the value of these clinical milestones against the broader market's valuation concerns and the necessity for continued pipeline conversion to drive future revenue.
📈 Q2 2026 revenue reached USD 10.05 billion, up 9.5% year over year.
💰 EPS of USD 6.29 beat consensus by USD 0.67.
🧬 Phase 3 results for dazodalibep in Sjogren's disease were positive.
⚖️ Scotiabank raised price target to USD 500; HSBC cut to USD 425.
📊 Full-year EPS guidance of USD 22.30-23.50 near consensus.
📈 Amgen reported Q2 2026 revenue of USD 10.05 billion, up 9.5 percent year over year.
💰 The company posted EPS of USD 6.29, beating the consensus estimate by USD 0.67.
🧬 Amgen announced positive topline Phase 3 results for dazodalibep in Sjogren's disease on September 22, 2026.
⚖️ Scotiabank raised its price target to USD 500.00 and maintained an Outperform rating.
📉 HSBC downgraded Amgen to Hold and cut its price target to USD 425.00.
📊 The company provided full-year EPS guidance of USD 22.30-23.50, near the consensus estimate.
🔬 Further studies are required for dazodalibep before a regulatory filing can be submitted.
💼 Amgen's market capitalization stands at USD 228.6 billion as of September 30, 2026.
Bullish Signals
Q2 2026 revenue reached USD 10.05 billion, up 9.5% YoY.
EPS of USD 6.29 beat consensus by USD 0.67.
Phase 3 dazodalibep results positive for Sjogren's disease.
Scotiabank raised price target to USD 500 with Outperform.
Risk Factors
HSBC downgraded to Hold, cut target to USD 425.00.
Dazodalibep needs further studies before regulatory filing.
Market weighs clinical progress against valuation concerns.
Bullish Signals
Amgen reported Q2 2026 revenue of USD 10.05 billion, representing a 9.5 percent year-over-year increase.
The company delivered EPS of USD 6.29, significantly beating the consensus estimate by USD 0.67.
Amgen achieved positive topline Phase 3 results for dazodalibep in Sjogren's disease, advancing its late-stage pipeline.
Scotiabank raised its price target to USD 500.00 and maintained an Outperform rating on the stock.
Risk Factors
HSBC downgraded Amgen to Hold and cut its price target to USD 425.00, citing valuation concerns.
Further studies are still necessary for dazodalibep before a regulatory filing can be pursued.
The market is weighing recent clinical progress against broader concerns about valuation and future competition.
Amgen (AMGN) recently received positive topline data from its Phase 3 OASIZ 301 trial for dazodalibep in Sjögren's disease, a development that has renewed investor attention on the company's autoimmune pipeline. This clinical success coincides with significant stock performance, including a 27.6% gain year-to-date and a 5-year total shareholder return of 131.0%, suggesting strong longer-term momentum despite recent price volatility.
Despite the positive catalysts, the article presents a conflicting valuation narrative where AMGN trades at $418.13, above the average analyst target but below intrinsic value estimates derived from discounted cash flow (DCF) models. While one analysis suggests the stock is 16% overvalued based on multiples, an alternative DCF framework indicates the shares trade roughly 38% below estimated future cash flow value of $673.80, highlighting a divergence in market assumptions regarding the company's earning power and legacy drug erosion.
The article outlines specific structural risks that could impact Amgen's growth trajectory, particularly concerning its position in the GLP-1 obesity market. Key concerns include a lack of domestic manufacturing infrastructure compared to competitors like Eli Lilly and Novo Nordisk, regulatory friction surrounding the CNPV pilot program, and the fact that Amgen is a late entrant in a crowded arena where incumbents already hold fast-track approvals. Additionally, the company faces significant headwinds from legacy high-margin drugs like Prolia and Enbrel, which are currently eroding at a rate of 30% or more year-over-year.
📈 Phase 3 OASIZ 301 data boosts autoimmune pipeline attention.
📊 Stock up 27.6% YTD with 131.0% five-year total return.
💰 Trades at $418.13, above analyst targets but below DCF value.
⚠️ Lacks domestic GLP-1 supply chain compared to Eli Lilly and Novo Nordisk.
📉 Legacy drugs Prolia and Enbrel eroding over 30% year-over-year.
📈 Amgen reported positive topline data from its Phase 3 OASIZ 301 trial for dazodalibep in Sjögren's disease, boosting attention on its autoimmune pipeline.
📊 The stock has climbed 27.6% year-to-date and achieved a 5-year total shareholder return of 131.0%, indicating strong longer-term momentum.
💰 AMGN currently trades at $418.13, which is above the average analyst target but below some intrinsic value estimates derived from DCF models.
⚠️ The company lacks massive domestic GLP-1 supply chain infrastructure compared to competitors like Eli Lilly and Novo Nordisk.
🏛️ The CNPV pilot program faces severe legal durability and structural transparency questions, creating regulatory friction for future growth.
🐢 Amgen is a latecomer in the obesity market where incumbents like Novo Nordisk already secured fast-track approvals via CNPV.
📉 Legacy high-margin drugs Prolia and Enbrel are eroding at a brutal negative 30% or more year-over-year clip.
🔍 A DCF model suggests AMGN trades about 37.9% below an estimated future cash flow value of $673.80, implying potential underestimation of earning power.
📉 Another valuation analysis concludes that AMGN is priced for flawless execution with zero margin of safety against structural vacuum.
🚀 If Amgen executes smoothly on dazodalibep and stabilizes legacy drug erosion, it could put pressure on the cautious market narrative.
Bullish Signals
Phase 3 OASIZ 301 trial data validated autoimmune pipeline potential.
Stock gained 27.6% YTD with 131.0% five-year TSR.
DCF model shows stock trades 37.9% below estimated value.
Risk Factors
CNPV pilot faces severe legal risks by mid-2026.
Obesity market crowded; Novo Nordisk holds fast-track tokens.
Amgen reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, validating its autoimmune pipeline potential.
The stock has delivered a 27.6% gain year-to-date and a 5-year total shareholder return of 131.0%, reflecting strong longer-term momentum.
A DCF model estimates AMGN trades about 37.9% below an estimated future cash flow value of $673.80, suggesting the market may be underestimating its earning power.
Risk Factors
The CNPV pilot program faces severe legal durability and structural transparency questions in mid-2026, posing a high-risk gamble for a 2027 thesis.
Amgen is a latecomer in the obesity market where incumbents like Novo Nordisk already hold fast-track tokens, creating a crowded arena.
Legacy high-margin drugs Prolia and Enbrel are eroding at a brutal negative 30% or more year-over-year clip, pressuring top-line growth.
The stock trades above the average analyst target, with some narratives framing the recent autoimmune win as already fully priced in.
Amgen Inc. stock closed at USD 418.60 on September 28, 2026, representing a gain of 0.96% from the previous close of USD 414.61. The trading activity reflects ongoing investor interest in the biotechnology firm's pipeline developments and regulatory milestones.
Significant progress was made for Amgen's IMDELLTRA therapy following an FDA approval on September 14, 2026, which updated prescribing information to reduce recommended monitoring time from 22 to 24 hours to just 6 to 8 hours in a healthcare setting. This regulatory change streamlines administration protocols and could enhance the drug's operational efficiency.
Earlier in September, Amgen announced positive interim results for its Phase 3 DeLLphi-305 study involving IMDELLTRA combined with AstraZeneca's Imfinzi. The trial met its primary endpoint of statistically significant improvement in overall survival compared to Imfinzi alone, while also achieving secondary endpoints for progression-free survival and objective response rate across 563 randomized patients.
These developments highlight Amgen's strategic advancements in oncology treatments, potentially strengthening its market position by improving patient outcomes and reducing clinical monitoring burdens. The combination therapy results suggest a robust efficacy profile that could influence future prescribing patterns and competitive dynamics within the immunotherapy sector.
📈 AMGN stock rose 0.96% to USD 418.60 on September 28, 2026.
✅ FDA approved reduced monitoring for IMDELLTRA first two doses.
🔬 Phase 3 DeLLphi-305 study met primary survival endpoint with IMDELLTRA plus Imfinzi.
📊 Trial of 563 patients met secondary endpoints for progression-free survival and response rate.
💼 Combination therapy showed enhanced efficacy versus Imfinzi alone in pivotal study.
📈 Amgen stock traded at USD 418.60 on September 28, 2026, gaining 0.96% from the prior close of USD 414.61.
✅ The FDA approved an update to IMDELLTRA prescribing information on September 14, 2026, reducing monitoring requirements from 22-24 hours to 6-8 hours for the first two doses.
🔬 Amgen's Phase 3 DeLLphi-305 study met its primary endpoint at an interim analysis in early September 2026, showing statistically significant overall survival improvement with IMDELLTRA plus Imfinzi.
📊 The DeLLphi-305 trial randomized 563 patients and successfully met secondary endpoints for progression-free survival and objective response rate.
💼 Amgen's combination therapy of IMDELLTRA with AstraZeneca's Imfinzi demonstrated enhanced efficacy compared to Imfinzi alone in the pivotal study.
Bullish Signals
FDA approved IMDELLTRA to reduce monitoring time to 6-8 hours.
DeLLphi-305 met primary endpoint with Imfinzi for overall survival.
Trial achieved secondary endpoints in 563 patients validating efficacy.
Bullish Signals
Amgen received FDA approval on September 14, 2026, to reduce monitoring time for IMDELLTRA from 22-24 hours to 6-8 hours, streamlining clinical administration and potentially improving patient compliance.
The Phase 3 DeLLphi-305 study met its primary endpoint of statistically significant overall survival improvement when IMDELLTRA was combined with AstraZeneca's Imfinzi compared to Imfinzi alone.
Amgen successfully achieved secondary endpoints in the DeLLphi-305 trial, including progression-free survival and objective response rate, validating the combination therapy's efficacy across 563 randomized patients.
Amgen Inc. shares closed at USD 410.86 on September 25, 2026, representing a gain of 1.19 percent or USD 4.82 from the previous session's close of USD 406.04. The stock opened at USD 408.25 and traded within an intraday range of USD 6.81, reaching a high of USD 411.00 before settling slightly below that peak.
The performance of Amgen's stock outpaced the broader market indices during the session, rising significantly more than the S&P 500's 0.53 percent advance. At the time of the report at 1:17:34 p.m. ET, trading volume stood at 684,284 shares, with the share price remaining well below its 52-week high of USD 447.03.
Market conditions on September 25 were influenced by declining oil prices and elevated long-term yields, with the 10-year Treasury yield at 5.225 percent. While Amgen's gain was solid, it trailed healthcare peer Moderna, which rose 1.46 percent, as broader market uncertainty persisted regarding geopolitical risks and monetary policy.
Analyst consensus for Amgen remained a Hold recommendation with a target price of USD 389.22 according to data from September 25. The stock maintained a substantial buffer above its 52-week low of USD 269.77, indicating continued investor interest despite the gap below recent highs.
📈 AMGN stock closed up 1.19% at USD 410.86.
📊 Intraday high reached USD 411.00 with volume of 684,284 shares.
💰 Stock trades USD 36.17 below its 52-week high of USD 447.03.
📝 Analyst consensus is Hold with a price target of USD 389.22.
📈 Amgen stock closed at USD 410.86, up 1.19 percent or USD 4.82 from the prior session's close of USD 406.04.
📊 The share price opened at USD 408.25 and reached an intraday high of USD 411.00 before settling.
📉 Trading volume was recorded at 684,284 shares as of 1:17:34 p.m. ET on September 25, 2026.
🏆 Amgen's gain exceeded the S&P 500's 0.53 percent advance by 0.66 percentage points.
💰 The stock traded USD 36.17 below its 52-week high of USD 447.03 and USD 141.09 above its low.
🌍 Market gains were driven by declining oil prices, with the 10-year Treasury yield at 5.225 percent.
🔬 Amgen's performance trailed healthcare competitor Moderna, which rose 1.46 percent during the same session.
📝 Analyst consensus recommendation is Hold with a price target of USD 389.22 based on September 25 data.
Amgen's stock price increased by 4.34% on September 23, 2026, closing at $410.24 on the Nasdaq. This upward movement occurred despite a broader decline in the Nasdaq Composite, which fell 1.13% to close at 26,936.04 points.
The rally was primarily driven by positive late-stage clinical trial results for dazodalibep, an experimental treatment for Sjogren disease. The drug successfully met its primary endpoint in the trial, validating its efficacy and advancing its development profile toward potential regulatory approval.
📈 Amgen stock rose 4.34% to close at $410.24 on September 23, 2026.
🧬 Experimental drug dazodalibep met primary late-stage trial goal for Sjogren disease.
📈 Jefferies raised Amgen price target to $410.00 following positive trial data.
📈 Amgen stock rose 4.34% to close at $410.24 on September 23, 2026.
🧬 The experimental drug dazodalibep met its primary late-stage trial goal for Sjogren disease.
📈 Jefferies raised its price target for Amgen to $410.00 following the positive trial data.
Bullish Signals
Stock gained 4.34% after dazodalibep met Sjogren trial goal.
Jefferies raised price target to $410 on successful trial.
Bullish Signals
Amgen stock gained 4.34% on September 23, 2026, closing at $410.24 after dazodalibep met its primary late-stage trial goal for Sjogren disease.
Analyst firm Jefferies raised its price target to $410.00 following the successful trial results for the experimental treatment.
Amgen Inc. shares rose 4.34% to close at $410.24 on September 22, 2026, driven by positive Phase 3 trial data for its drug candidate dazodalibep in Sjogren's disease. The OASIZ 301 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the company's pipeline outlook and investor sentiment regarding future commercial potential.
Financially, Amgen reported robust quarterly performance for the period ended June 30, 2026, delivering $10.05 billion in revenue and $6.29 in earnings per share. The EPS of $6.29 notably exceeded the consensus estimate of $5.62 by $0.67, while revenue grew 9.5% compared to the same quarter last year, demonstrating solid operational execution.
Analyst reaction was positive, with Jefferies raising its price target for Amgen stock from $367 to $410 following the news, although maintaining a Hold rating. The firm also increased its peak sales estimate for dazodalibep to $4.5 billion from $1 billion, highlighting the material valuation impact of the successful trial results.
Looking ahead, the company maintained its fiscal year 2026 EPS guidance range of $22.30 to $23.50, which aligns closely with analyst consensus. The next critical milestone is the OASIZ-303 data expected in the fourth quarter of 2026, which must be reported before a regulatory filing can be submitted for dazodalibep.
📈 Amgen stock gained 4.34% to $410.24 on positive dazodalibep Phase 3 data.
💰 Quarterly revenue hit $10.05B and EPS reached $6.29, beating estimates by $0.67.
📊 Revenue grew 9.5% year-over-year, reinforcing financial stability for fiscal year 2026.
🚀 Jefferies raised price target to $410 and peak dazodalibep sales estimate to $4.5B.
⏳ OASIZ-303 study data expected in Q4 2026 before regulatory filing.
📈 Amgen stock closed at $410.24 on September 22, 2026, gaining 4.34% as positive Phase 3 data for dazodalibep in Sjogren's disease lifted pipeline hopes.
💰 The company reported quarterly revenue of $10.05 billion and EPS of $6.29 for the quarter ended June 30, 2026, beating the consensus estimate by $0.67.
📊 Revenue grew 9.5% year-over-year, exceeding market expectations and reinforcing Amgen's financial stability during the fiscal year 2026.
🚀 Jefferies raised its price target for AMGN from $367 to $410 and increased peak sales estimates for dazodalibep to $4.5 billion following the trial success.
🔬 The OASIZ 301 Phase 3 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, validating the drug candidate's efficacy.
⏳ Another study (OASIZ-303) must report before regulatory filing, with data expected in the fourth quarter of 2026.
🎯 Amgen maintained fiscal year 2026 EPS guidance of $22.30 to $23.50, showing confidence in its near-term earnings delivery despite narrow consensus alignment.
📉 The stock trades at a P/E ratio of 25.50 with a market capitalization of $221.79 billion as of September 22, 2026.
Bullish Signals
Stock rose 4.34% to $410.24 on positive dazodalibep trial data.
Revenue hit $10.05B and EPS of $6.29, beating estimates by $0.67.
Jefferies raised price target to $410 and peak dazodalibep sales to $4.5B.
OASIZ 301 Phase 3 met primary endpoint boosting pipeline outlook.
Risk Factors
Dazodalibep regulatory filing depends on pending OASIZ-303 study results.
OASIZ-303 data not expected until Q4 2026, delaying commercial validation.
Bullish Signals
Amgen stock rose 4.34% to close at $410.24 on September 22, 2026, directly driven by positive Phase 3 trial data for dazodalibep in Sjogren's disease.
The company reported quarterly revenue of $10.05 billion and EPS of $6.29, with EPS beating the consensus estimate by $0.67.
Revenue grew 9.5% year-over-year compared to the comparable quarter ended June 30, 2026, demonstrating strong top-line performance.
Jefferies raised its price target for AMGN from $367 to $410 and increased peak sales estimates for dazodalibep to $4.5 billion following the successful trial.
The OASIZ 301 Phase 3 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the pipeline outlook.
Risk Factors
Another study (OASIZ-303) must report before regulatory filing can be submitted for dazodalibep, creating a dependency on future clinical milestones.
The OASIZ-303 data is not expected until the fourth quarter of 2026, leaving a gap before the commercial case for dazodalibep can be fully tested.
Amgen (AMGN) shares surged approximately 4% in premarket trading to reach $406.02 following the announcement of positive topline results from its Phase 3 clinical trial, OASIZ 301, for dazodalibep, an experimental treatment for Sjögren's disease. The study met its primary endpoint, demonstrating statistically meaningful improvements in systemic disease activity at Week 48 as measured by the ESSDAI index among 621 patients with moderate-to-severe conditions.
The trial data indicated that therapeutic benefits were observable as early as Week 4 and persisted through the full 48-week duration. Dazodalibep functions as a CD40L antagonist fusion protein designed to disrupt immune cell interactions driving the autoimmune disease. Notably, there are currently no FDA-approved medicines for Sjögren's, positioning dazodalibep as a potential first-in-class therapy if regulatory approval is granted.
Safety profiles observed in the trial were manageable, with common side effects including nasopharyngitis and hypertension occurring at mild to moderate levels. Discontinuation rates due to adverse events were low and comparable between treatment and placebo groups. Amgen plans to present full data at an upcoming medical conference, while a second Phase 3 study is expected to conclude in Q4 2026.
📈 AMGN stock rose ~4% premarket after positive Phase 3 dazodalibep results.
✅ OASIZ 301 met primary endpoint showing improvement at Week 48.
💊 Dazodalibep is a CD40L antagonist targeting immune cells for Sjögren's.
🛡️ Safety data showed low discontinuation rates with mild side effects.
🚀 Approval would make dazodalibep the first FDA treatment for Sjögren's.
📈 AMGN stock jumped roughly 4% in premarket trading to hit $406.02 after reporting positive Phase 3 trial results for its Sjögren's disease drug, dazodalibep.
✅ The OASIZ 301 study met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.
🔬 Dazodalibep demonstrated early efficacy improvements as soon as Week 4 that held through the end of the 48-week trial period.
💊 The drug is a CD40L antagonist fusion protein targeting T cells, B cells, and other immune cells to disrupt disease-driving interactions.
🛡️ Safety data showed low discontinuation rates due to side effects, which were mild to moderate and similar across treatment and placebo groups.
🚀 If approved, dazodalibep would be the first FDA-approved treatment for Sjögren's, a systemic autoimmune disease currently lacking approved medicines.
📅 Amgen plans to present full data from OASIZ 301 at an upcoming medical conference to provide further clarity on the drug's profile.
🔭 A second Phase 3 study, OASIZ 303, is underway and expected to wrap up in Q4 2026 for patients with moderate-to-severe symptomatic Sjögren's disease.
Bullish Signals
Stock jumped 4% to $406.02 on positive Phase 3 results.
OASIZ 301 trial met primary endpoint at Week 48.
Dazodalibep showed benefits by Week 4 through Week 48.
Drug is potential first-in-class therapy for Sjögren's.
Bullish Signals
Amgen stock jumped roughly 4% in premarket trading to hit $406.02 following positive topline results from the Phase 3 trial of its experimental Sjögren's disease drug, dazodalibep.
The OASIZ 301 trial met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.
Dazodalibep demonstrated therapeutic benefits as early as Week 4 that persisted through the full 48-week period of the study.
The drug represents a potential first-in-class therapy for Sjögren's, a condition currently lacking any FDA-approved medicines.
Amgen stock recently closed at USD 385.65 on the Nasdaq on September 18, 2026, positioning it just below the average analyst target price of approximately USD 387.69. The company has demonstrated strong earnings momentum in recent quarters, consistently beating market expectations and driving a positive market reaction that saw shares rise around 1.55% following the latest session.
Analyst consensus data compiled around mid-September 2026 indicates that while the current price leaves limited immediate upside from the average target, there remains significant potential for growth relative to the high analyst objective of USD 457.00. The stock has gained roughly 17.82% since the start of 2026, reflecting investor confidence in its earnings trajectory and solid fundamental performance within the large-cap healthcare sector.
Beyond earnings beats, Amgen benefits from a robust history of dividend growth, earning an A- grade for dividend growth alongside peers like AbbVie. This consistent payout track record makes the stock attractive to income-oriented investors, while the company maintains a substantial market capitalization of approximately USD 208.45 billion as of September 21, 2026.
📈 AMGN stock closed at $385.65 below analyst average target of $387.69.
Holds A- dividend grade with robust payout history.
Gained 17.82% since start of 2026.
Bullish Signals
Amgen stock recently closed at USD 385.65, trading just below the average analyst target of USD 387.69, signaling confidence from Wall Street analysts.
The company has reported strong earnings momentum in recent quarters with consistent beats versus market expectations, driving a positive 1.55% share price move.
Amgen holds an A- grade for dividend growth, demonstrating a robust history of increasing payouts that appeals to income-oriented investors.
The stock has gained approximately 17.82% since the start of 2026, indicating sustained investor confidence in its fundamental performance.
Amgen's stock price surged on September 18, 2026, closing at $385.65 on Nasdaq, representing a gain of 1.55% from the previous session. This positive market reaction was driven primarily by the company's updated financial outlook and its commitment to shareholder returns through a robust dividend program.
Management has officially raised its 2026 earnings per share guidance to a range of $22.30 to $23.50. This upward revision signals strong confidence within the biotech group that its core business operations are sufficient to cover and grow its dividend payments, moving away from reliance on financial engineering tactics.
Amgen maintains an attractive dividend profile for investors, paying a quarterly dividend of $2.52 per share. When annualized, this results in a total payout of $10.08 per share, implying a yield of approximately 2.6% at the current share price, which has attracted significant attention from income-focused investors.
📈 Amgen stock rose 1.55% to $385.65 on Sept 18, 2026.
🚀 Management raised 2026 EPS guidance to $22.30–$23.50 range.
💰 Company pays quarterly dividend of $2.52, annualizing to $10.08.
📊 Current price implies approximately 2.6% dividend yield for investors.
🛡️ Leadership confirms operating performance will cover and grow the dividend.
📈 Amgen stock closed at $385.65 on September 18, 2026, gaining 1.55% following positive news.
🚀 Management raised 2026 earnings per share guidance to a range of $22.30 to $23.50.
💰 The company pays a quarterly dividend of $2.52, annualizing to $10.08 per share.
📊 The current share price implies a dividend yield of approximately 2.6% for investors.
🛡️ Leadership signals confidence that operating performance will cover and grow the dividend.
Bullish Signals
Stock surged 1.55% to $385.65 on Sept 18, 2026.
Management raised 2026 EPS guidance to $22.30-$23.50.
Offers strong 2.6% dividend yield with $10.08 annual payout.
Bullish Signals
Amgen stock surged 1.55% to close at $385.65 on September 18, 2026, driven by rising earnings guidance.
Management raised 2026 EPS guidance to a range of $22.30 to $23.50, demonstrating confidence in business growth.
The company offers a strong dividend yield of approximately 2.6% with an annualized payout of $10.08 per share.
Amgen (AMGN) stock valuation has seen a modest lift as analyst models update fair value targets from US$371.93 to US$388.03, reflecting shifts in revenue growth assumptions from 2.93% to 3.50% and net profit margin expectations rising to 25.15%. This adjustment incorporates a slightly higher future P/E multiple of 25.1x and a discount rate increase to 7.96%, signaling evolving market pricing for the biopharmaceutical giant.
Market sentiment remains mixed among major financial institutions, with several firms including UBS, Argus, TD Cowen, Scotiabank, Oppenheimer, Barclays, Bernstein, Wells Fargo, and Piper Sandler raising price targets to a US$420-US$460 range. These bullish moves cite strong commercial execution, recent Q2 earnings beats, higher guidance, and robust long-term sales potential for key cholesterol and cardiovascular franchises like Repatha and Lipfendra.
Conversely, HSBC downgraded Amgen to Hold with a reduced target of US$425, while BMO Capital adopted a neutral Market Perform stance at US$450. These bearish adjustments highlight concerns over ongoing loss of exclusivity on existing products, competitive pressures from biosimilars, and the need for greater clarity on the sales trajectory of its pipeline candidate MariTide.
📈 Analysts raise Amgen fair value targets to US$388-US$460 citing earnings beats.
💊 Prescription data supports higher long-term sales for Repatha and Lipfendra.
⚠️ BMO warns of exclusivity losses and MariTide competitive uncertainty risks.
🧬 Late-stage pipeline in obesity and oncology could drive future high-margin launches.
📈 Amgen's updated analyst model raises fair value price target to US$388.03 from US$371.93, reflecting improved revenue growth assumptions and profit margin expectations.
🔍 Multiple analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised targets to US$420-US$460 citing strong product portfolio performance and Q2 earnings beats.
💊 Wells Fargo and Piper Sandler increased targets to US$435 based on prescription data supporting higher long-term sales for Repatha and Lipfendra.
📉 HSBC downgraded Amgen to Hold and cut its target to US$425, noting that current stock price aligns closely with fair value with limited near-term upside.
⚠️ BMO Capital shifted to a neutral Market Perform rating at US$450 due to ongoing loss of exclusivity headwinds and uncertainty surrounding MariTide's competitive profile.
📊 Analyst models show revenue growth assumption shifting from 2.93% to 3.50% while net profit margin expectations rise from 24.84% to 25.15%.
🧬 Key investment themes include Amgen's late-stage pipeline in obesity, type 2 diabetes, cardiovascular disease, and oncology which could drive future high-margin launches.
🛡️ Strategic diversification efforts focus on biosimilars portfolio expansion, digital transformation initiatives, and reaching under-treated patient groups to stabilize revenue base.
⚖️ Primary risks identified include drug pricing pressure, biosimilar competition affecting products like Prolia, heavy R&D and manufacturing spend, and regulatory uncertainty.
Bullish Signals
Analysts raised price targets to US$420-US$460 citing strong execution and earnings beats.
Barclays and Bernstein highlighted product strength and higher guidance for confident forecasts.
Wells Fargo lifted target to US$435 based on Repatha and Lipfendra sales potential.
Fair value target increased from US$371.93 to US$388.03 with improved revenue growth assumptions.
Net profit margin assumptions adjusted upward from 24.84% to 25.15% for stronger profitability.
Risk Factors
HSBC downgraded to Hold with $425 price target.
BMO neutral at $450 citing exclusivity loss risks.
Risks include pricing pressure, biosimilars, and R&D spend.
Bullish Signals
Analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised price targets to a US$420-US$460 range citing strong commercial execution and Q2 earnings beats.
Barclays and Bernstein highlighted broad product strength and higher guidance as support for confident forecasts of Amgen's execution across key franchises.
Wells Fargo and Piper Sandler lifted targets to US$435 based on external survey work and prescription data supporting higher long-term sales potential for Repatha and Lipfendra.
Updated analyst model increases fair value price target from US$371.93 to US$388.03, reflecting improved revenue growth assumptions shifting from 2.93% to 3.50%.
Net profit margin assumptions have been adjusted upward from 24.84% to 25.15%, indicating analysts expect stronger profitability in the coming periods.
Risk Factors
HSBC downgraded Amgen to Hold and cut its price target to US$425, stating that after strong execution the stock price more closely matches fair value with limited near-term upside.
BMO Capital shifted to a neutral Market Perform stance at US$450 citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile of MariTide.
Key risks include drug pricing pressure, biosimilar competition on products such as Prolia, heavy R&D and manufacturing spend, regulatory uncertainty, and demographic shifts.
Amgen (AMGN) shares dropped approximately 5% on September 16, 2026, closing lower on the Nasdaq amid a broader sector downturn. The decline was primarily driven by fresh clinical data in the cardiovascular space that negatively impacted investor sentiment across the biopharmaceutical industry.
The stock's performance suffered significantly from Novartis' recent failure in cardiovascular medicine trials, which created a ripple effect throughout the sector. As Amgen holds a substantial weighting in the Dow Jones Industrial Average, it was disproportionately affected by the index's 1.21% fall and the specific reassessment of cardiometabolic drug pipelines following these setbacks.
Broader macroeconomic pressures further exacerbated the sell-off, with risk-off sentiment intensifying after the Federal Reserve signaled an upcoming rate hike. Investors are now closely monitoring Amgen's pipeline developments and broader market dynamics as they navigate this volatile environment.
📉 Amgen stock fell 5% on Sept 16, 2026, closing lower on Nasdaq.
💊 Cardiovascular clinical data weighed heavily on Amgen's performance decline.
Amgen stock closed at $381.96 on September 14, 2026, rising 1.1 percent to outperform the broader market as the S&P 500 and Nasdaq Composite declined.
The positive price movement was driven by specific regulatory developments regarding the company's oncology portfolio rather than general sector trends or macroeconomic factors.
Key catalysts included FDA approval for Imdelltra, a bispecific T-cell engager therapy, which now features a reduced monitoring time requirement. This regulatory win simplifies the treatment protocol and is expected to positively influence adoption trends within the oncology market.
📈 Amgen shares rose 1.1% to $381.96 on Sept 14, 2026.
✅ FDA approved Imdelltra with reduced monitoring time requirements.
🔬 Regulatory milestone drives adoption for Amgen's oncology pipeline.
📈 Amgen shares gained 1.1 percent to close at $381.96 on September 14, 2026, defying a broader market decline where the S&P 500 fell 0.5 percent.
✅ The FDA granted approval for Imdelltra with a reduced monitoring time requirement, streamlining the administration protocol for this bispecific T-cell engager therapy.
🔬 This regulatory milestone is expected to drive adoption trends for Amgen's oncology pipeline by making the treatment more accessible and operationally efficient.
Bullish Signals
Stock rose 1.1% to $381.96, outperforming S&P 500 and Nasdaq.
FDA approval for Imdelltra simplifies protocol, accelerating oncology adoption.
Bullish Signals
Amgen stock rose 1.1 percent to $381.96, outperforming the S&P 500 and Nasdaq Composite during a broader market decline.
The FDA approval for Imdelltra with reduced monitoring time simplifies the treatment protocol, potentially accelerating adoption in the oncology sector.
Amgen (AMGN) shares have experienced a sharp five-day decline of approximately 15%, erasing roughly $36 billion from its market capitalization and leaving the stock trading at about $204 billion. This significant drop contrasts with broader market performance, as the S&P 500 declined by only 1.2% during the same period, placing Amgen among a select group of stocks facing substantial selling pressure.
The recent selloff is directly attributed to clinical trial fallout in the cardiovascular space, specifically following Novartis's failure to meet its primary endpoint for its pelacarsen study. This event cast doubt on the commercial viability of Amgen's competing Phase 3 candidate, olpasiran, triggering a direct spillover effect that drove down AMGN shares despite the company's otherwise sturdy underlying business metrics.
Despite the short-term price action, Amgen reports robust trailing fundamentals with revenue growth of 9.1% over the last twelve months and an operating margin of 30.0%, both exceeding S&P 500 medians. The stock currently trades at a price-to-earnings multiple of 23.3, which is below the sector median of 25.1, while maintaining a healthy free cash flow yield of 5.0%.
Longer-term performance remains positive with returns of +7.2% over three months and +39.2% over twelve months, suggesting the recent slide may represent a market reassessment rather than a fundamental deterioration. Analysts view such streaks as signals to re-evaluate investment theses against underlying business data rather than immediate instructions to alter positions.
📉 Stock fell 15% in five days, erasing $36B value due to Novartis trial impact.
📈 Revenue grew 9.1% YoY, outpacing S&P 500 median of 8.3%.
💰 Operating margins hit 30.0%, well above the 18.6% sector median.
📊 P/E multiple is 23.3, trading below the Health Care sector median of 25.1.
💵 Free cash flow yield stands at 5.0% with strong generation capabilities.
📉 Amgen stock has fallen 15% over five consecutive trading days, erasing approximately $36 billion in market value.
💊 The decline is linked to Novartis's failed Phase 3 trial for pelacarsen, which negatively impacted investor sentiment toward Amgen's competing olpasiran candidate.
📈 Revenue growth remains strong at 9.1% year-over-year, outpacing the S&P 500 median of 8.3% over the trailing twelve months.
💰 Operating margins stand at 30.0%, significantly higher than the 18.6% median for the broader index.
📊 The stock trades at a P/E multiple of 23.3, which is below the Health Care sector median of 25.1.
💵 Amgen maintains a free cash flow yield of 5.0%, indicating solid cash generation capabilities.
📅 Longer-term momentum persists with +7.2% returns over the trailing three months and +39.2% over twelve months.
Bullish Signals
Revenue grew 9.1%, exceeding S&P 500 median of 8.3%.
Operating margin stands at 30.0%, well above index median.
Free cash flow yield is 5.0%, showing strong generation.
Stock returned +7.2% in three months and +39.2% yearly.
Risk Factors
Shares dropped 15% in 5 days, erasing $36B value.
Competitor trial failure casts doubt on olpasiran viability.
Joining 45 S&P 500 stocks with 5-day losing streak.
Bullish Signals
Revenue growth of 9.1% over the last twelve months exceeds the S&P 500 median of 8.3%, demonstrating resilient top-line performance.
The company maintains a robust operating margin of 30.0%, which is well above the index median of 18.6%.
Amgen generates a free cash flow yield of 5.0%, reflecting strong cash generation relative to its market capitalization.
Despite recent volatility, the stock has delivered +7.2% returns over the trailing three months and +39.2% over twelve months.
Risk Factors
Shares have dropped 15% over five consecutive days, erasing $36 billion in market value due to a sharp selloff.
The stock price fell following Novartis's failed Phase 3 trial for pelacarsen, casting doubt on the commercial viability of Amgen's competing olpasiran candidate.
The recent decline places AMGN among 45 other S&P 500 stocks on losing streaks of five days or more, indicating significant short-term momentum weakness.
Amgen stock fell approximately 1.34% to close at USD 377.35 on September 11, 2026, following a downgrade from Buy to Hold by HSBC. The bank cut its price target to USD 425 from USD 445, arguing that the stock has re-rated significantly after strong execution and now trades close to fair value. This sentiment is reinforced by a consensus analyst price target of roughly USD 381.68, which sits only about USD 4 above the current share price, signaling limited near-term upside.
Despite the negative analyst reaction, Amgen reported robust financial results for the second quarter of 2026. Revenue rose 9.5% year-over-year to reach USD 10.05 billion, surpassing consensus estimates of USD 9.43 billion. Diluted earnings per share also beat expectations, coming in at USD 6.29 compared to an analyst forecast of USD 5.62, representing a 4.5% increase from the prior-year quarter.
Key growth drivers include the cholesterol-lowering drug Repatha, which generated USD 953 million in revenue during the quarter, up 37% sequentially. Analysts are now focusing on upcoming pipeline readouts, particularly data from the MariTide obesity trial, as the next major catalyst for the company amidst intensifying competition in the therapeutic space.
The market capitalization of Amgen stood at USD 204.01 billion at the time of the close. While the stock remains well below its 52-week high of USD 447.03, it sits roughly USD 107 above its low. The prevailing analyst sentiment is balanced, with ratings split between Buy, Hold, and Sell categories, suggesting investors are weighing current earnings strength against future trial outcomes.
📉 HSBC downgraded AMGN to Hold with a USD 425 price target.
Amgen (AMGN) received a downgrade to Market Perform from Outperform at BMO Capital on Tuesday, September 8, 2026. The analyst firm adjusted its rating for the biotech giant while maintaining a price target of $450 per share.
This negative analyst action occurred amidst a broader market environment where Wall Street returned from summer vacation to brace for potential Federal Reserve rate hikes following strong August payrolls data that crushed expectations.
The downgrade represents a shift in sentiment regarding the company's outlook, contrasting with other recent analyst moves in the sector such as upgrades for Intel and Lockheed Martin, though specific fundamental drivers for Amgen's downgrading were not detailed in this report.
📉 BMO downgraded AMGN to Market Perform from Outperform.
💰 BMO maintains $450 price target for AMGN shares.
📅 Analyst action occurred on Tuesday, September 8, 2026.
📉 Amgen was downgraded to Market Perform from Outperform by BMO Capital.
💰 BMO Capital maintains a $450 price target for Amgen shares following the rating change.
📅 The analyst action took place on Tuesday, September 8, 2026, as part of a daily roundup of Wall Street research calls.
Risk Factors
Downgraded to Market Perform by BMO Capital.
Reduced confidence in near-term prospects due to Fed rate hike fears.
Risk Factors
Amgen was downgraded to Market Perform from Outperform by BMO Capital, signaling reduced analyst confidence in the company's near-term prospects.
The downgrade occurred while the broader market faced pressure from strong employment data that increased the likelihood of a Federal Reserve rate hike.
Amgen Inc. (NASDAQ: AMGN) reported solid Q2 2026 financial results with revenue reaching $10.1 billion, representing a 10% year-over-year increase. Non-GAAP EPS rose 4% to $6.29, driven by robust growth in key products which increased 26%. The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and shareholder returns.
Despite positive momentum in its core portfolio, Amgen faces significant headwinds from biosimilar competition affecting its mature franchises. Revenue from Prolia declined 32% while XGEVA revenue fell 34%. To counter these challenges, management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting erosion with new product launches and pipeline assets like olpasiran.
Analyst sentiment remains positive, with Wells Fargo raising its price target to $435 from $400 on September 4. The firm cited potential upside from the cardiovascular drug HORIZON and the expanded mortality benefits of Repatha, which recently showed a 20% reduction in death risk for high-risk adults. Hedge fund positioning also shows support, with major investors like D.E. Shaw increasing their stakes significantly.
The article concludes that while Amgen presents a viable investment case supported by strong cash flow and pipeline potential, investors must monitor the effectiveness of new launches against biosimilar erosion. The company's ability to maintain margin expansion will depend on successfully navigating competitive pressures in legacy segments while capitalizing on growth opportunities in oncology and cardiovascular therapies.
📈 Amgen Q2 revenue rose 10% to $10.1B with EPS up 4%.
Amgen reported Q2 2026 revenue of $10.1 billion, a 10% year-over-year increase driven by robust growth in key products which advanced 26%.
The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and strategic initiatives.
Management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting biosimilar erosion with new launches.
Wells Fargo raised its price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline assets like olpasiran.
Repatha recently showed a 20% reduction in death risk for high-risk adults, with heart attack risk reductions emerging as early as six months.
Risk Factors
Mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34% in Q2 2026.
Accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
Amgen stock experienced a severe decline of 10.1% on September 8, 2026, closing at $393.17 on the Nasdaq. This drop represents the company's steepest single-day fall in approximately 25 years, signaling significant investor concern regarding its current trajectory and market position.
The primary driver of this downturn was a Phase 3 clinical trial setback for Novartis' pelacarsen, an injectable cholesterol-targeting therapy. Investors interpreted this failure as a negative signal for the broader class of similar drugs, raising specific concerns about the efficacy and future prospects of Amgen's own portfolio in the same therapeutic area.
Market sentiment was further weighed down by analyst action from BMO Capital Markets, which cut its rating on Amgen to 'market perform' while maintaining a price target of $450. This downgrade reflects a cautious outlook for the biotechnology giant amidst the challenging environment for cholesterol-lowering treatments.
📉 Amgen stock dropped 10.1% to $393.17, worst decline in ~25 years.
⚠️ Novartis pelacarsen setback raises concerns for Amgen's similar therapies.
📉 BMO downgraded Amgen to 'market perform' with $450 price target.
📉 Amgen stock plummeted 10.1% on September 8, 2026, closing at $393.17 to mark its steepest single-day decline in roughly 25 years.
⚠️ Investors expressed concern that a Phase 3 setback for Novartis' pelacarsen injectable cholesterol drug negatively impacts the outlook for Amgen's similar therapies.
📉 BMO Capital Markets downgraded Amgen to 'market perform' while maintaining a price target of $450, reflecting cautious sentiment on the stock.
BMO cut rating to 'market perform' despite $450 target.
Risk Factors
Amgen shares suffered their steepest single-day decline in about 25 years, dropping 10.1% to close at $393.17.
A Phase 3 setback for Novartis' pelacarsen raised investor concerns regarding the viability of similar cholesterol-targeting therapies within Amgen's own pipeline.
BMO Capital Markets cut its rating on Amgen to 'market perform', indicating a negative shift in analyst sentiment despite maintaining a $450 price target.
Amgen (AMGN) shares fell 10% to $394.38 in Tuesday trading, driven by a sector-wide repricing of Lp(a) cholesterol drugs following Novartis's failed pelacarsen trial. Despite Amgen posting positive Phase 3 results for its IMDELLTRA study in small cell lung cancer on the same morning, investors penalized the company heavily due to its exposure to the broader Lp(a) hypothesis.
The market reaction highlights a specific risk to Amgen's pipeline: its Olpasiran asset, an Lp(a)-lowering therapy currently in Phase 3 OCEAN(a)-Outcomes trials, is now viewed as highly exposed to the class-wide skepticism triggered by Novartis. Analysts suggest that while the mechanism of lowering Lp(a) might be flawed or the trial design at issue, the immediate consequence is a re-rating of all remaining programs in this space.
Amgen's cholesterol franchise remains robust, with Repatha generating $876 million in Q1 2026 revenue and growing 34% year-over-year. However, the stock's decline underscores the market's tendency to treat pipeline assets as correlated bets, even when distinct molecules like Amgen's Olpasiran and Eli Lilly's VERVE-102 utilize different technical approaches.
Looking ahead, investors are advised to monitor follow-up commentary from cardiology leaders and await Amgen's presentation at the 2026 Wells Fargo Healthcare Conference. This upcoming event is expected to be a key catalyst for reframing the narrative around the Lp(a) class and determining whether the recent selloff reflects a failed drug or a fundamental failure of the underlying hypothesis.
📉 Stock dropped 10% amid Lp(a) class concerns after Novartis trial failure.
🧬 IMDELLTRA showed positive Phase 3 results with AstraZeneca's Imfinzi.
⚠️ Olpasiran faces re-rating risk due to Novartis cardiovascular trial miss.
💰 Repatha drove $876M Q1 revenue with 34% year-over-year growth.
📅 Investors await Wells Fargo conference for Lp(a) hypothesis clarity.
📉 Amgen stock dropped 10% to $394.38, interrupting a 23% year-to-date gain, as markets punished the company for its exposure to the Lp(a) drug class following Novartis's trial failure.
🧬 Amgen announced positive Phase 3 results for IMDELLTRA in small cell lung cancer on the same day, showing statistically significant improvement in overall survival with AstraZeneca's Imfinzi.
⚠️ The company's Olpasiran asset is identified as the most exposed pipeline item to the class-wide re-rating caused by Novartis's pelacarsen miss in the cardiovascular outcomes trial.
💰 Repatha continues to drive growth, generating $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume expansion.
📅 Investors are watching for Amgen's presentation at the 2026 Wells Fargo Healthcare Conference as the next major catalyst to clarify the Lp(a) hypothesis viability.
🏛️ As a major holding in the Health Care Select Sector SPDR ETF (XLV), Amgen's decline contributed to sector pressure despite Novartis not being a direct component of the fund.
Bullish Signals
IMDELLTRA met Phase 3 endpoint with significant overall survival improvement.
Repatha drove $876M Q1 2026 revenue with 34% YoY growth.
Risk Factors
Shares fell 10% due to sector-wide repricing of Lp(a) pipeline risk.
Investors reweighted odds on cardiovascular programs after Novartis trial failure.
Bullish Signals
Amgen successfully met its primary endpoint in the Phase 3 DeLLphi-305 study for IMDELLTRA, demonstrating statistically significant improvement in overall survival for extensive stage small cell lung cancer.
Repatha remains a high-growth driver within the cholesterol franchise, delivering $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume growth.
Risk Factors
Amgen shares fell 10% as the market repriced Lp(a) pipeline risk sectorwide following Novartis's failed pelacarsen trial, directly impacting Amgen's Olpasiran asset.
The failure of Novartis's pelacarsen study has weakened the Lp(a) hypothesis, forcing investors to reweight the odds on Amgen's remaining cardiovascular programs despite its own positive oncology data.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)